文献速递淋巴瘤

维奈克拉联合R-CHOP一线治疗弥漫大B细胞淋巴瘤的2期研究

A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
PubMed 文献 · Blood · 2021-01-01

CAVALLI 2期研究评估维奈克拉联合R-CHOP一线治疗初治弥漫大B细胞淋巴瘤(DLBCL),纳入206例患者。治疗结束完全缓解率69%,中位随访32.2个月,总人群无进展生存期风险比0.61(95%CI 0.43-0.87),Bcl-2免疫组化阳性亚组风险比0.55(95%CI 0.34-0.89),3/4级血液学不良事件发生率86%,治疗相关死亡率2%。

要点

  • 维奈克拉联合R-CHOP在初治DLBCL中完全缓解率69%,Bcl-2阳性亚组一致。
  • 中位随访32.2个月,无进展生存期风险比总人群0.61,Bcl-2阳性亚组0.55。
  • 3/4级血液学不良事件发生率86%,但治疗相关死亡率仅2%,骨髓抑制可控。

核心结论

  • 维奈克拉联合R-CHOP一线治疗DLBCL增加但可控的骨髓抑制,并显示潜在疗效改善,尤其在高危Bcl-2免疫组化阳性亚组。

研究设计与样本

  • 2期CAVALLI研究(NCT02055820),纳入206例初治DLBCL患者,年龄≥18岁,ECOG体能状态≤2,国际预后指数2-5。
  • 维奈克拉800 mg(第1周期第4-10天,第2-8周期第1-10天)联合利妥昔单抗(8周期)和环磷酰胺、多柔比星、长春新碱、泼尼松(6-8周期),21天为一周期。
  • 主要终点为安全性、耐受性和治疗结束完全缓解率;次要终点为无进展生存期和总生存期;采用GOYA/BO21005研究R-CHOP对照进行协变量调整比较分析。

主要发现

  • 治疗结束完全缓解率总体人群为69%,Bcl-2免疫组化阳性亚组保持一致。
  • 中位随访32.2个月,研究者评估的无进展生存期趋势改善:总人群风险比0.61(95%CI 0.43-0.87),Bcl-2免疫组化阳性亚组风险比0.55(95%CI 0.34-0.89)。
  • 3/4级血液学不良事件发生率86%,治疗相关死亡率2%,化疗剂量强度与GOYA研究相似。

关键数值与推荐

  • 治疗结束完全缓解率总体人群69%。
  • 无进展生存期风险比总人群0.61(95%CI 0.43-0.87),Bcl-2免疫组化阳性亚组0.55(95%CI 0.34-0.89)。
  • 3/4级血液学不良事件发生率86%,治疗相关死亡率2%。

临床怎么用

  • 维奈克拉联合R-CHOP可作为初治DLBCL的潜在治疗选择,尤其在高危Bcl-2免疫组化阳性患者中。
  • 治疗期间需监测骨髓抑制,但治疗相关死亡率未增加,支持其可管理性。

局限性

  • 为2期单臂研究,与GOYA/BO21005研究的R-CHOP对照比较采用协变量调整,非随机对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phase 2 CAVALLI (NCT02055820) study assessed efficacy and safety of venetoclax, a selective B-cell lymphoma-2 (Bcl-2) inhibitor, with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line (1L) diffuse large B-cell lymphoma (DLBCL), including patients demonstrating Bcl-2 protein overexpression by immunohistochemistry (Bcl-2 IHC+). Eligible patients were ≥18 years of age and had previously untreated DLBCL, Eastern Cooperative Oncology Group performance status ≤2, and International Prognostic Index 2 to 5. Venetoclax 800 mg (days 4-10, cycle 1; days 1-10, cycles 2-8) was administered with rituximab (8 cycles) and cyclophosphamide, doxorubicin, vincristine, and prednisone (6-8 cycles) in 21-day cycles. Primary end points were safety, tolerability, and research_plete response (CR) at end of treatment (EOT). Secondary end points were progression-free survival (PFS) and overall survival. Comparative analyses used covariate-adjusted R-CHOP controls from the GOYA/BO21005 study, an appropriate contemporary benchmark for safety and efficacy. Safety and efficacy analyses included 206 patients. CR rate at EOT was 69% in the overall population and was maintained across Bcl-2 IHC+ subgroups. With a median follow-up of 32.2 months, trends were observed for improved investigator-assessed PFS for venetoclax plus R-CHOP in the overall population (hazard ratio [HR], 0.61; 95% confidence interval [CI], 0.43-0.87) and Bcl-2 IHC+ subgroups (HR, 0.55; 95% CI, 0.34-0.89) vs R-CHOP. Despite a higher incidence of grade 3/4 hematologic adverse events (86%), related mortality was not increased (2%). Chemotherapy dose intensity was similar in CAVALLI vs GOYA. The addition of venetoclax to R-CHOP in 1L DLBCL demonstrates increased, but manageable, myelosuppression and the potential of improved efficacy, particularly in high-risk Bcl-2 IHC+ patient subgroups.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Morschhauser F, Feugier P, Flinn IW, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021. PMID: 33538797. doi:10.1182/blood.2020006578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。